NASDAQ:ONTX Onconova Therapeutics (ONTX) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free ONTX Stock Alerts $1.00 0.00 (-0.47%) (As of 04/2/2024) Add Compare Share Share Today's Range$0.77▼$1.0050-Day Range$0.67▼$1.0152-Week Range$0.55▼$1.45Volume1.28 million shsAverage Volume96,681 shsMarket Capitalization$20.90 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial Media Get Onconova Therapeutics alerts: Email Address Onconova Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,005.2% Upside$11.00 Price TargetShort InterestHealthy0.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.72) to ($0.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.00 out of 5 starsMedical Sector784th out of 910 stocksPharmaceutical Preparations Industry367th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingOnconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOnconova Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.12% of the outstanding shares of Onconova Therapeutics have been sold short.Short Interest Ratio / Days to CoverOnconova Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconova Therapeutics has recently increased by 26.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOnconova Therapeutics does not currently pay a dividend.Dividend GrowthOnconova Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONTX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Onconova Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ONTX on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Onconova Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Onconova Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 7.95% of the stock of Onconova Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Onconova Therapeutics are expected to decrease in the coming year, from ($0.72) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Onconova Therapeutics is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Onconova Therapeutics is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOnconova Therapeutics has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Onconova Therapeutics Stock (NASDAQ:ONTX)Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Read More ONTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONTX Stock News HeadlinesApril 24, 2024 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Now Covered by StockNews.comApril 16, 2024 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Coverage Initiated at StockNews.comApril 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 4, 2024 | uk.investing.comOnconova and Trawsfynydd merge to form Traws PharmaApril 4, 2024 | finance.yahoo.comTraws Pharma Full Year 2023 Earnings: Beats ExpectationsApril 3, 2024 | msn.comNewtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with TrawsfynyddApril 2, 2024 | markets.businessinsider.comOnconova Acquires Trawsfynydd To Form Traws PharmaApril 2, 2024 | globenewswire.comTraws Pharma Announces New Employee Inducement GrantsApril 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 12, 2024 | msn.comOnconova to Unveil New Rigosertib Study Results at Cancer Research MeetingMarch 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)March 8, 2024 | finance.yahoo.comOnconova Therapeutics’ Rigosertib Poster Selected for AACR 2024March 8, 2024 | globenewswire.comOnconova Therapeutics' Rigosertib Poster Selected for AACR 2024February 13, 2024 | investing.comOnconova Therapeutics Inc (ONTX)January 23, 2024 | finance.yahoo.comOnconova Therapeutics, Inc. (ONTX)December 21, 2023 | benzinga.comOnconova Therapeutics Stock (NASDAQ:ONTX) Dividends: History, Yield and DatesDecember 12, 2023 | msn.comOnconova stock falls 10% on preclinical data for lymphoma drugDecember 12, 2023 | finance.yahoo.comOnconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell LymphomaDecember 8, 2023 | finance.yahoo.comOnconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’sNovember 28, 2023 | finance.yahoo.comOnconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity ConferenceNovember 16, 2023 | finance.yahoo.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call TranscriptNovember 16, 2023 | finanznachrichten.deOnconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial ResultsNovember 14, 2023 | finance.yahoo.comOnconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial ResultsNovember 7, 2023 | finance.yahoo.comOnconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023November 2, 2023 | benzinga.comOnconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCLNovember 2, 2023 | finance.yahoo.comOnconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCLOctober 19, 2023 | markets.businessinsider.comPromising Developments in Onconova Therapeutics’ Drug Narazaciclib Bolster Buy Rating: An AnalysisSee More Headlines Receive ONTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today4/23/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONTX CUSIPN/A CIK1130598 Webwww.onconova.com Phone(267) 759-3680Fax267-759-3681Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+1,005.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,960,000.00 Net Margins-8,930.97% Pretax Margin-8,930.97% Return on Equity-95.43% Return on Assets-61.19% Debt Debt-to-Equity RatioN/A Current Ratio2.79 Quick Ratio2.79 Sales & Book Value Annual Sales$230,000.00 Price / Sales90.88 Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book0.74Miscellaneous Outstanding Shares21,000,000Free Float20,310,000Market Cap$20.90 million OptionableOptionable Beta1.38 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Steven M. Fruchtman M.D. (Age 73)CEO, President & Director Comp: $907.86kMr. Mark Patrick Guerin CPA (Age 55)CFO & COO Comp: $629.27kDr. Victor Moyo M.D.Chief Medical OfficerKey CompetitorsIndaptus TherapeuticsNASDAQ:INDPVincerx PharmaNASDAQ:VINCRenovoRxNASDAQ:RNXTTherapeuticsMDNASDAQ:TXMDAddex TherapeuticsNASDAQ:ADXNView All Competitors ONTX Stock Analysis - Frequently Asked Questions Should I buy or sell Onconova Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ONTX shares. View ONTX analyst ratings or view top-rated stocks. What is Onconova Therapeutics' stock price target for 2024? 1 brokerages have issued twelve-month price objectives for Onconova Therapeutics' shares. Their ONTX share price targets range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 1,005.2% from the stock's current price. View analysts price targets for ONTX or view top-rated stocks among Wall Street analysts. How have ONTX shares performed in 2024? Onconova Therapeutics' stock was trading at $0.7456 at the beginning of the year. Since then, ONTX shares have increased by 33.5% and is now trading at $0.9953. View the best growth stocks for 2024 here. Are investors shorting Onconova Therapeutics? Onconova Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 26,200 shares, an increase of 26.6% from the March 15th total of 20,700 shares. Based on an average daily volume of 41,700 shares, the days-to-cover ratio is presently 0.6 days. View Onconova Therapeutics' Short Interest. When is Onconova Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ONTX earnings forecast. How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.06 million. Onconova Therapeutics had a negative trailing twelve-month return on equity of 95.43% and a negative net margin of 8,930.97%. During the same quarter in the prior year, the business posted ($0.45) earnings per share. When did Onconova Therapeutics' stock split? Onconova Therapeutics's stock reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Onconova Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM). How do I buy shares of Onconova Therapeutics? Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONTX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconova Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
